Abstract
BackgroundPrior work on real-world burden of moderate RA patients highlighted low health-related quality of life (HRQOL) and high disease burden at time of biologic therapy initiation [1]. The impact of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
